2017-03-14,Achaogen Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-03-06,Achaogen To Host Conference Call And Webcast Of Fourth Quarter And Year 2016 Financial Results On March 14, 2017
2017-03-02,Achaogen To Present At The Cowen And Company 37th Annual Health Care Conference
2017-03-01,Achaogen Highlights Emerging Pipeline Of Antibacterials Including A New Orally-Administered Antibiotic Clinical Candidate At Company's R&D Day
2017-02-28,Achaogen Announces New Employment Inducement Grants
2017-02-27,Achaogen Adds Janet Dorling As Chief Commercial Officer
2017-02-23,Achaogen Announces Leadership Promotions
2017-02-22,Achaogen Announces Achievement Of A Key Milestone In Developing A Plazomicin Assay To Support Therapeutic Drug Management (TDM)
2017-02-15,Achaogen To Host R&D Day Focused On Advances And Opportunities In The Treatment Of Resistant Gram-Negative Infections
2017-02-09,Achaogen To Participate In The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-31,Trading Action Has Improved, Here's What I Am Playing
2017-01-19,Jump on Harley Davidson, but Stay Away From Costamare: 'Mad Money' Lightning Round
2017-01-18,Earnings, Not Just the Trump Rally, Drive Stocks: Cramer's 'Mad Money' Recap (Wednesday 1/18/17)
2017-01-13,Surge From Bank Earnings Doesn't Last
2017-01-05,Achaogen Appoints Halley Gilbert To Its Board Of Directors
2017-01-05,Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified
2017-01-04,Trying to Knock Out Some Individual Trades, but it Is not Easy
2016-12-19,Achaogen Announces Closing Of Public Offering Including Exercise Of Underwriters' Option To Purchase Additional Shares
2016-12-15,Markets Are Rising But Feel Confused
2016-12-14,Machines Are Pumping Up the Volume
2016-12-14,Achaogen Announces Pricing Of Public Offering Of Common Stock
2016-12-13,AKAO Crosses Above Average Analyst Target
2016-12-12,Achaogen Announces Proposed Public Offering Of Common Stock
2016-12-12,Achaogen Announces Positive Results In Phase 3 CUTI And CRE Clinical Trials Of Plazomicin
2016-12-11,Achaogen To Host Conference Call And Webcast To Review Plazomicin Phase 3 Clinical Results
2016-11-22,Achaogen Announces New Employment Inducement Grants
2016-11-15,Achaogen Adds Gary Loeb As General Counsel
2016-11-10,Achaogen To Present At The Stifel Healthcare Conference 2016
2016-11-07,Achaogen Reports Third Quarter 2016 Financial Results And Announces Acceleration Of Expected Timeline For Reporting Top-Line Results From Plazomicin Program
2016-11-01,Achaogen To Host Conference Call And Webcast Of Third Quarter 2016 Financial Results On November 7, 2016
2016-10-24,Achaogen To Present First Plazomicin CARE Trial Data In Patients With Carbapenem-Resistant Enterobacteriaceae (CRE) Infections At IDWeek 2016
2016-09-29,5 Stocks Under $10 Poised for Big Breakouts
2016-09-27,Achaogen Announces New Employment Inducement Grants
2016-09-01,Achaogen Completes Patient Enrollment In Phase 3 EPIC Clinical Trial Of Plazomicin
2016-08-22,Achaogen Announces New Employment Inducement Grants
2016-08-10,Achaogen To Present At The Wedbush PacGrow Healthcare Conference
2016-08-08,Achaogen Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-07-15,Achaogen To Host Key Opinion Leader Meeting On Multi-Drug Resistant Infections On July 19, 2016 In New York
2016-07-06,Achaogen Announces New Employment Inducement Grants
2016-06-24,Achaogen Announces New Employment Inducement Grants
2016-06-20,Achaogen's Plazomicin Highlighted In Multiple Presentations At ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens
2016-06-13,Achaogen (AKAO) Is Strong On High Volume Today
2016-06-09,Achaogen Announces Plazomicin Data Presentations At ASM Microbe 2016 Annual Meeting
2016-06-06,Achaogen (AKAO) Stock: Weak On High Volume Today
2016-06-03,Trade-Ideas: Achaogen (AKAO) Is Today's Strong On High Relative Volume Stock
2016-06-03,Achaogen Adds Tobin Schilke As Chief Financial Officer
2016-06-02,Achaogen Awarded $20 Million Contract Option By BARDA To Support Development Of Plazomicin For Multi-Drug Resistant Gram-Negative Infections
2016-06-02,Achaogen Raises $25 Million In Private Placement
2016-06-02,Achaogen Reaches 50 Percent Patient Enrollment In Phase 3 EPIC Registration Trial Of Plazomicin
2016-05-10,Achaogen And Crystal Bioscience Enter Into Collaboration And License Agreement To Identify And Develop Antibodies For Multiple Targets
2016-05-05,Achaogen Reports First Quarter 2016 Financial Results
2016-04-22,Achaogen Announces New Employment Inducement Grants
2016-04-21,Achaogen Awarded $2.4 Million Contract Option By NIAID To Support Development Of LpxC Inhibitors For The Treatment Of Serious Bacterial Infections
2016-04-15,7 Stocks Under $10 Making Big Moves
2016-04-06,Achaogen To Present At The 15th Annual Needham Health Care Conference
2016-04-05,Achaogen Announces Acceleration Of Expected Timeline For Reporting Top-Line Results From Phase 3 EPIC Registration Clinical Trial Of Plazomicin
2016-03-15,Achaogen Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-03-08,Achaogen To Host Conference Call And Webcast Of Fourth Quarter And Year 2015 Financial Results On March 15, 2016
2016-02-08,Achaogen And TRIANNI Sign Licensing Agreement For Use Of Trianni Transgenic Mouse Platform
2016-01-21,Achaogen Joins Leading International Healthcare Companies In Declaration To Further Mobilize Governments To Combat The Threat Of Antimicrobial Resistance
2016-01-11,Achaogen Announces Enrollment Of First Patient In EPIC, A Phase 3 Clinical Trial For The Treatment Of Complicated Urinary Tract Infections (cUTI) With Plazomicin
2015-12-17,Achaogen Announces Employment Inducement Grants
2015-11-05,Achaogen Announces Third Quarter 2015 Results
2015-11-04,Achaogen To Present At 2015 Credit Suisse Healthcare Conference
2015-10-06,Achaogen Announces Employment Inducement Grants
2015-09-15,Achaogen To Present Data On Plazomicin At 55th Annual ICAAC Meeting
2015-08-19,Achaogen Appoints Blake Wise As Chief Operating Officer
2015-08-17,5 Stocks Ready for Breakouts
2015-08-10,Achaogen Announces Second Quarter 2015 Results
2015-08-05,Achaogen To Present At The 2015 Wedbush PacGrow Healthcare Conference
2015-07-21,Achaogen Announces Employment Inducement Grants
2015-07-16,Achaogen Awarded $4.5 Million Contract With NIAID For Development Of Novel LpxC Inhibitors For The Treatment Of Bacterial Infections
2015-07-09,5 Stocks Under $10 Set to Soar
2015-07-01,Achaogen To Present At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-06-18,4 Breakout Biotech Stocks Under $10 to Watch
2015-06-15,Achaogen To Participate In BIO And AIA Events Focused On Incentivizing Antibiotic Development
2015-06-11,Achaogen Announces Appointment Of Greg Stea To Board Of Directors And Results Of Annual Meeting Of Stockholders
2015-05-21,5 Stocks Under $10 Set to Soar
2015-05-19,Ratings Changes Today
2015-05-11,Achaogen Provides Clinical Update And First Quarter 2015 Results
2015-05-05,Achaogen To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-04-30,Achaogen To Receive $7.1 Million In Settlement Of Claim With Defense Threat Reduction Agency (DTRA)
2015-04-09,Achaogen To Present At 14th Annual Needham Healthcare Conference
2015-03-30,Achaogen Announces Webcast Providing Update On Development Plan For Plazomicin
2015-03-25,Achaogen Becomes Oversold (AKAO)
2015-03-16,Achaogen Announces Fourth Quarter And Full Year 2014 Results
2015-03-12,Achaogen To Present At The Jefferies 2015 Antibiotic Summit On March 18, 2015
2015-03-12,Achaogen Announces Appointment Of Kent Lieginger And Alan Colowick To Board Of Directors
2015-02-25,Achaogen To Present At The Cowen And Company 35th Annual Health Care Conference On March 3, 2015
2015-01-08,Achaogen Announces Plazomicin Granted QIDP Designation By FDA
2014-11-10,Achaogen Announces Third Quarter 2014 Results
2014-10-29,Achaogen To Present At 2014 Credit Suisse Healthcare Conference
2014-09-17,Isis Pharmaceuticals Earns $4 Million From Achaogen For The Initiation Of A Phase 3 Study Of Plazomicin
2014-09-17,Achaogen Announces First Patient Enrollment In A Phase 3 Clinical Trial Of Plazomicin To Treat Infections Caused By Carbapenem-Resistant Enterobacteriaceae (CRE)
2014-08-11,Achaogen Announces Second Quarter 2014 Results
2014-07-14,Achaogen Appoints Dr. Ian Friedland As Chief Medical Officer
2014-07-09,Is antibiotic-resistant bacteria a curse or a blessing for Big Pharma?
,
,
